Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 10593 - 10600 of 12007 results
Data: Big, Borderless and Beyond Control? Five Things You Can Do
March 3, 2014| Blog| Viewpoint
Final Regulations Illustrate That Lock-Up Arrangements Do Not Prevent Current Taxation Under Section 83
March 3, 2014| Blog| Viewpoint
New York Council Amends Earned Sick Time Act Yet Again; Employers Must Comply by April 1, 2014
March 3, 2014| Blog| Viewpoint
Final Regulations Illustrate That Lock-Up Arrangements Do Not Prevent Current Taxation Under Section 83
February 28, 2014| Alert| Viewpoint
Risky Business: Target Discloses Data Breach and New Risk Factors in 8-K Filing… Kind Of
February 28, 2014| Blog| Viewpoint
Puerto Rico Senate Not in a New York State of Mind?
February 27, 2014| Blog| Viewpoint
Our Law360 Article Analyzing CPSC's Proposal to Expand Disclosure of Company & Product Information
February 27, 2014| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|